The market for oral anticoagulants has advanced significantly since warfarin was essentially the lone option. Still, in some cases, the use of improved direct oral anticoagulants (DOACs) can provoke ...
PHOENIX, AZ—Much like in the setting of acute ischemic stroke, shorter times to treatment are associated with better outcomes in patients with anticoagulation-associated intracerebral hemorrhage (ICH) ...
August 13, 2010 (Miami, Florida) — Researchers believe they may have found a truly reversible anticoagulant system to control bleeding during PCI that consists of one agent to anticoagulate and ...
Please provide your email address to receive an email when new articles are posted on . AIMS65 score predicted mortality and rebleeding for patients on anticoagulants with gastrointestinal bleeding.
LEIDEN, The Netherlands--(BUSINESS WIRE)--VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised ...
In the acute phase of oral anticoagulation-associated intracerebral hemorrhage (OAC-ICH), two factors can protect against hematoma enlargement: getting the international normalized ratio (INR) below 1 ...
Credit: Getty Images. Balfaxar is a non-activated 4 factor prothrombin complex concentrate containing vitamin K-dependent factors. The Food and Drug Administration (FDA) has approved Balfaxar ® ...
PARAMUS, N.J., July 26, 2023 – Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) has received U.S. Food and Drug ...
About The Study: In hospitals participating in Get With The Guidelines–Stroke, earlier anticoagulation reversal was associated with improved survival for patients with intracerebral hemorrhage. These ...
Direct oral anticoagulants (DOACs) have transformed venous thromboembolism (VTE) treatment by offering predictable pharmacokinetics and eliminating routine monitoring requirements. Despite robust ...
WILMINGTON, Del.--(BUSINESS WIRE)--ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of ANDEXXA (andexanet alfa) in patients on oral FXa inhibitor treatment including ...
Every day, surgeons are faced with the task of ensuring that their patients do not experience blood clotting during the invasive procedure. Clots can be potentially life-threatening, since they can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results